Clinical Trials Logo

Clinical Trial Summary

Betahistine may provide benefit by enhancement of Cerebral Blood Flow (CBF). This placebo-controlled pharmacodynamic treatment study will primarily explore the effect of betahistine on cerebral blood flow measured by dynamic contrast-enhanced MRI imaging, in a patient population with MRI evidence of cerebrovascular compromise. Also it will be measured if CBF changes correlate with gait and cognitive changes.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Gait or Balance Disorder Problems

NCT number NCT01468285
Study type Interventional
Source Abbott
Contact
Status Completed
Phase Phase 4
Start date February 2012
Completion date April 2013